StreetInsider.com News Articles

Apogee Therapeutics Inc (APGE) PT Lowered to $116 at Deutsche Bank

Wed, 03 Jun 2026 07:14:25 -0400

Deutsche Bank analyst David Hoang lowered the price target on Apogee Therapeutics Inc (NASDAQ: APGE) to $116.00 (from $118.00) while maintaining a Buy rating.

Apogee Therapeutics to Participate in Upcoming June Conferences

Thu, 28 May 2026 16:01:00 -0400

SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.

Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Fireside Time: 11:40 a.m. ET

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Wednesday, June 10, 2026
Fireside Time: 9:20 a.m. ET

A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing

Apogee Therapeutics to Participate in Upcoming June Conferences

Thu, 28 May 2026 16:01:00 -0400

SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.

Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Fireside Time: 11:40 a.m. ET

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Wednesday, June 10, 2026
Fireside Time: 9:20 a.m. ET

A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing

Apogee Therapeutics to Participate in Upcoming June Conferences

Thu, 28 May 2026 16:01:00 -0400

SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.

Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Fireside Time: 11:40 a.m. ET

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Wednesday, June 10, 2026
Fireside Time: 9:20 a.m. ET

A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing

Apogee Therapeutics to Participate in Upcoming June Conferences

Thu, 28 May 2026 16:01:00 -0400

SAN FRANCISCO and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), today announced that members of management will participate at the following investor conferences.

Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Fireside Time: 11:40 a.m. ET

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Wednesday, June 10, 2026
Fireside Time: 9:20 a.m. ET

A live and archived webcast of the fireside chats will be available via the News & Events page in the Investors section of the Apogee Therapeutics website.

About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing

Apogee Therapeutics (APGE) July 70 puts active, share price down 5.7%

Wed, 27 May 2026 14:50:20 -0400

Apogee Therapeutics (NASDAQ: APGE) 30-day option implied volatility is at 53; compared to its 52-week range of 50 to 233 with a focus on July 70 puts as share price down 5.7%.

Apogee Therapeutics Inc (APGE) PT Lowered to $81 at Truist Securities

Wed, 27 May 2026 12:39:11 -0400

Truist Securities analyst Danielle Brill lowered the price target on Apogee Therapeutics Inc (NASDAQ: APGE) to $81.00 (from $83.00) while maintaining a Hold rating.

The analyst comments "Our views on APGE’s Part B data remain largely unchanged following this morning’s call. In short, while the results fell short of elevated expectations, we view the overall dataset as supportive of zumi's efficacy & safety profile in atopic dermatitis (AD). With added clinical validation, we raised our modeled PoS to 75% (from 70%) and incorporate the impact of the Blackstone (NR) synthetic royalty agreement. Net, our PT modestly declines to $81 (from $83).

Apogee Therapeutics Inc (APGE) PT Lowered to $81 at Truist Securities

Wed, 27 May 2026 12:39:11 -0400

Truist Securities analyst Danielle Brill lowered the price target on Apogee Therapeutics Inc (NASDAQ: APGE) to $81.00 (from $83.00) while maintaining a Hold rating.

Form 8-K Apogee Therapeutics, For: May 26

Wed, 27 May 2026 06:40:00 -0400

si-local-file:///var/storage/secattach/20260527/26553113.html

Form 8-K Apogee Therapeutics, For: May 26

Wed, 27 May 2026 06:40:00 -0400

si-local-file:///var/storage/secattach/20260527/26553113.html

Form 8-K Apogee Therapeutics, For: May 27

Wed, 27 May 2026 06:38:00 -0400

si-local-file:///var/storage/secattach/20260527/26553105.html

Form 8-K Apogee Therapeutics, For: May 27

Wed, 27 May 2026 06:38:00 -0400

si-local-file:///var/storage/secattach/20260527/26553105.html

Apogee Therapeutics shares jump on $1.3B Blackstone deal

Wed, 27 May 2026 06:36:09 -0400

Investing.com -- Shares of Apogee Therapeutics are trading approximately 16% higher in pre-market Wednesday after the company announced a $1.3 billion financing collaboration with Blackstone Life Sciences to fund the development and commercialization of zumilokibart, a treatment for atopic dermatitis.

The agreement includes up to $800 million in synthetic royalty funding and up to $500 million in senior corporate debt, available with mutual consent from both parties. Blackstone will receive low-to-mid single digit tiered royalties on worldwide annual sales of zumilokibart for 15 years, with no royalties on global annual sales exceeding $8 billion.

The synthetic royalty funding is structured in tranches.

Apogee secures $1.3 billion financing deal with Blackstone for drug development

Wed, 27 May 2026 06:31:17 -0400

Apogee Therapeutics Inc. (NASDAQ: APGE) announced a strategic financing collaboration with Blackstone Life Sciences providing up to $1.3 billion in non-dilutive capital to support development and commercialization of zumilokibart, a treatment for atopic dermatitis.

The agreement includes up to $800 million in synthetic royalty funding and up to $500 million in senior corporate debt available at mutual consent of both parties. Blackstone will receive low-to-mid single digit tiered royalties on worldwide annual sales of zumilokibart for 15 years, with no royalties on global annual sales exceeding $8 billion.